X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TGN-S11 is an E5 oncogene protein Inhibitor small molecule drug candidate, which is being evaluated in combination with pembrolizumab for the treatment of HPV-Induced Cancer.
Lead Product(s): TGN-S11,Pembrolizumab
Therapeutic Area: Oncology Product Name: TGN-S11
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
TGN-S11 is a small molecule that is inhibits the E5 oncogene of HPV, which is investigated for the treatment of Human Papillomavirus(HPV) Induced Cancer.
Lead Product(s): TGN-S11,Pembrolizumab
Therapeutic Area: Oncology Product Name: TGN-S11
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
TGN-S11 is a small molecule that is inhibits the E5 oncogene of HPV, which is investigated for the treatment of Human Papillomavirus(HPV) Induced Cancer.
Lead Product(s): TGN-S11,Pembrolizumab
Therapeutic Area: Oncology Product Name: TGN-S11
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Details:
TGN-S11 is a Small Molecule that is inhibits the E5 oncogene of HPV, which is investigated for the treatment of Human Papillomavirus(HPV) Induced Cancer.
Lead Product(s): TGN-S11,Pembrolizumab
Therapeutic Area: Oncology Product Name: TGN-S11
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2023
Details:
TGN-S11 was initially developed and approved as anti-microbial drug. It has been discovered that it decreases the growth of HPV+ tumor cells and improves survival in mice with HPV+ tumors.
Lead Product(s): TGN-S11
Therapeutic Area: Infections and Infectious Diseases Product Name: TGN-S11
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
Toragen is ready to begin a Phase I Clinical trial of single agent TGN-S11 in 12-15 patients with HPV associated malignancies. This will be a dose escalation study with the primary endpoint being feasibility, safety, and toxicity.
Lead Product(s): TGN-S11
Therapeutic Area: Infections and Infectious Diseases Product Name: TGN-S11
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
